<br/>Caspase-1 is an endogenous cysteine protease formed as an inactive pro-caspase-1 and activated by dimerization and auto proteolysis within multiprotein complexes including adaptor ASC and nod-like receptor family such as NLRP3 called inflammasomes by linking microbial and endogenous danger signals to caspase-1 activation. Activated caspase-1 is required for IL-1 β and IL-18 release, cell death, and plays a key role in inflammation. Several diseases are associated with the dysregulated activation of caspase-1 and IL-1β secretion. Targeting proteases and specifically caspases via small molecule therapeutics is an active area of research. Herein, we present our strategy for the design and synthesis of small molecule inhibitors of the caspase 1 as a therapeutic potential for the treatment of inflammatory disease. Inhibitors were screened with fluorometric method. The level of inhibition of caspase-1 activity has been analyzed by comparing with and without testing inhibitors.

Therapeutic potential of the caspase 1 inhibitors for the treatment of inflammatory disease

2019 Fall National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.